



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-AZ-PCT-US/JPW/GJG/ML		Serial No. 10/816,329						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelhana et al.								
					Filing Date March 31, 2004		Group						
U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate	
	1	5	8	8	9	0	2	6	3/30/99	Alanine et al.			
	2	6	1	1	7	8	7	8	9/12/00	Linden			
	3	6	4	6	5	4	5	6	10/15/02	Springer et al.			
	4	6	6	8	0	3	2	2	1/20/04	Castelhano et al.			
	5	6	9	1	6	8	0	4	7/12/05	Castelhano et al.			
	6	7	2	0	2	2	5	2	4/10/07	Wilson et al.			
	7	20	03	01	39	4	2	7	11/1/05	Castelhano et al.			
	8	20	03	02	29	0	6	7	12/11/03	Castelhano et al.			
	9	20	04	00	82	5	9	8	4/29/04	Castelhano et al.			
	10	20	04	00	82	5	9	9	4/29/04	Castelhano et al.			
	11	20	05	01	19	2	7	1	6/2/05	Castelhano et al.			
	12	10	0	1	0	0	9	2	11/30/01	Castelhano et al.			
FOREIGN PATENT DOCUMENTS													
		Document Number						Date	Country	Class	Subclass	Translation	
												Yes	No
	13	12	4	6	6	2	3	B1	8/9/06	EPO			
	19	20	01	03	9	7	7	7	6/7/01	PCT			
	20	20	02	05	7	2	6	7	7/25/02	PCT			
	21	20	03	04	8	1	2	0	6/12/03	PCT			
	22	20	03	05	3	3	6	1	7/3/03	PCT			
	23	20	03	05	3	3	6	6	7/3/03	PCT			
	24	9	7	4	7	6	0	1	12/18/97	PCT			
	25	9	9	6	4	4	0	7	12/16/99	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
	14	Hungarian Patent No. HU P9303515 (corresponds to WO 94/13676)											
	15	Hungarian Patent No. HU P9501230 (corresponds to WO 95/19970)											
	16	Hungarian Patent No. HU P9602013 (corresponds to WO 95/19970)											
	17	Hungarian Patent No. HU P9402829 (corresponds to WO 93/20078)											
	18	Hungarian Patent No. HU P9602017 (corresponds to WO 95/19774)											
	26	International Search Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001											
	27	International Search Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002											
	28	International Search Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002											
	29	International Search Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002											
	30	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001											
	31	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002											
	32	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002											
	33	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002											
EXAMINER								DATE CONSIDERED					
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>													

Applicants: Arlindo Castelhana et al.
 Serial No.: 10/816,329
 Filed: March 31, 2004
 Exhibit A

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-AZ-PCT-US/JPW/GJG/ML		Serial No. 10/816,329	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelhana et al.			
					Filing Date March 31, 2004		Group	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	34	Partial European Search Report; for EP Application No. 01 99 7029; completed 12/21/2004						
	35	Partial European Search Report; for EP Application No. 06 01 6543.8; completed 10/4/2006						
	36	Supplemental European Search Report; for EP Application No. 02 80 5676; issued 2/7/2005						
	37	Baraldi, P.G. et al., (1999) "A1 and A3 adenosine receptor agonists: an overview." <i>Expert Opinion on Therapeutic Patents</i> , 9(5):515-527						
	38	Baraldi, P.G. (2003) "Recent developments in the field of A2A and A3 adenosine receptor antagonists" <i>Eur. J. Med. Chem.</i> 38(4) 367						
	39	Baraldi, P.G. et al., (1999) "A1 and A3 adenosine receptor agonists: an overview." <i>Expert Opinion on Therapeutic Patents</i> , 9(5):515-527						
	40	Baraldi, P.G. et al., (2004) "Allosteric modulators for the A1 adenosine receptor." <i>Expert Opinion on Therapeutic Patents</i> , 14(1):71-79						
	41	Borman, S. (2001) "A3 Receptors" <i>C&EN</i> , 79(7), 37						
	42	Bremer et al. (2002) "Therapy of Crohn's Disease in Childhood", <i>Expert Opin. Pharmacother.</i> 3(7): 809-825						
	43	Christofi, F.L. et al. (2001), "Differential Gene Expression of Adenosine A1, A2a, A2b, and A3 Receptors in the Human Enteric Nervous System", <i>J. Comp. Neurol.</i> 439(1): 46-64						
	44	Corset, V. et al. (2000), "Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor", <i>Nature</i> , 407 (6805): 747-750						
	45	Dubey, R.K. et al. (2001), "A2B Receptors Mediate the Antimitogenic Effects of Adenosine in Cardiac Fibroblasts", <i>Hypertension</i> 37: 716-721						
	46	Faivre, K. et al., (2001) "Suppression of Cellular Invasion by Activated G-Protein Subunits Gao, Gai1, and Gai3 and Sequestration of Gβγ", <i>Mol. Pharmacol.</i> 60: 363-372						
	47	Feoktistov, I. and Biaggioni, I., (1997) "Adenosine A2B Receptors", <i>Pharmacol. Rev.</i> 49(4): 381-402						
	48	Feoktistov, I. et al., (2002) "Differential Expression of Adenosine Receptors in Human Endothelial Cells", <i>Circulation Research</i> 90: 531-538						
	49	Fishman P (2003) "Pharmacology and therapeutic applications of A3 receptor subtype" <i>Curr. Top. Med. Chem.</i> 3(4): 463-9						
	50	Gao, Z. et al., "A2B Adenosine and P2Y2 Receptors Stimulate Mitogen-activated Protein Kinase in Human Embryonic Kidney-293 Cells" <i>J. Bio. Chem.</i> (1999) 274(9): 5972-5980						
	51	Grant, M.B. et al., (2001) "Proliferation, Migration, and ERK Activation in Human Retinal Endothelial Cells through A2B Adenosine Receptor Stimulation", <i>Invest. Ophthalmol. Vis. Sci.</i> 42(9): 2068-2073						
	52	Guo, Y. et al., (2001) "Targeted deletion of A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning." <i>J Mol Cell Cardiol</i> , 33:825-830						
	53	Haynes, J. Jr. et al., (1999) "5-(N-ethylcarboxamido) adenosine desensitizes the A2b-adenosine receptor in lung circulation", <i>Am. J. Physiol.</i> 276(6): H1877-H1883						
	54	Herndon, J.L. et al., (1992) Herndon, J.L. et al., "Ketanserin Analogs: Structure-Affinity Relationships for 5-HT2 and 5-HT1C Serotonin Receptor Binding", <i>J. Med. Chem.</i> 35(26): 4903-4910						
	55	Hoeschst India Ltd., India "Pharmacologically active pyrimido "[4,5-b]indoles and their salts." Database accession No. 106:84629 HCA XP002121648						
EXAMINER				DATE CONSIDERED				
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-AZ-PCT-US/JPW/GJG/ML		Serial No. 10/816,329	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelhana et al.			
					Filing Date March 31, 2004		Group	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	56	Kiichiro, K. et al. "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" Chem. Abstracts 56:8713						
	57	Kiritsy, J.A. et al., (1978) "Synthesis and Quantitative Structure-Activity Relationships of Some Antibacterial 3-Formylrifamycin SV N-(4-Substituted phenyl) piperazinoacethydrzones" J. Med. Chem. 21(12): 1301-1307						
	58	Klumpp, D.A. et al., (1999) "Synthesis of Aryl-Substituted Piperidines by Superacid Activation of Piperidones" J. Org. Chem. 64(18): 6702-6705						
	59	Linden, J. et al., (1998) "The Structure and Function of A1 and A2B Adenosine Receptors" Life Sciences 62(17-18): 1519-1524						
	60	Meade et al., PubMed Abstract (Life Sci. 69(11):1225-40) August 2001						
	61	Michell, C.H. (1999) "A3 adenosine receptors regulate C1-channels of nonpigmented ciliary epithelial cells" Am. J. Physiol. 276: C659-C666						
	62	Mirabet, M. et al., (1999) "Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation" J. Cell. Sci. 112(4): 491-502						
	63	Mitchell, C.H. et al., "Adenosine A3 Receptor Activation Reduces Cell Volume and Activates Cl ⁻ Current in Human Ciliary Epithelial Cells", <i>FASEB J</i> , A134 (Abstract only)						
	64	Müller, C.E. (2001) "A3 Adenosine Receptor Antagonists" Mini Reviews in Med. Chem. 1(4): 339						
	65	Müller, C.E. et al., "Imidazo [2,1-i] purin-5-ones and Related Tricyclic Water-Soluble Purine Derivatives: Potent A2A- and A3-Adenosine Receptor Antagonists", (2002) J. Med. Chem. 45(16): 3440-3450						
	66	Nagarathnam, D. et al., (1998) "Design and Synthesis of Novel α 1a Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia", J. Med. Chem. 41(26): 5320-5333						
	67	Nyce J.W. (1997) "DNA Antisense thrapy for asthma in an animal model" 385: 721. Walker (1997) Am. J. Respir. Cell Mol. Biol. 161: 531						
	68	Polosa (2002) "Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease", Eur. Respir. Journal 20,488-496						
	69	Priego, E.-M. et al., "Pyrido [2,1-f]purine-2,4-dione Derivatives as a Novel Class of Highly Potent Human A3 Adenosine Receptor Antagonists", (2002) J. Med. Chem., 45(16): 3337-3344						
	70	Ralevic, V. And Burnstock, G., (1998) "Receptors for Purines and Pyrimidines", Pharmacol. Rev. 50(3): 413-492						
	71	Regnauld, K. et al., (2002) "G-protein α olf subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells", Oncogene 21(25): 4020-4031						
	72	Robinson, "Medical Therapy of Inflammatory Bowel Disease for the 21st Century", Eur J Surg. Suppl 582:90-98, 1998						
	73	Simone, Oncology: Introduction Cecil Textbook of Medicine, 20th Edition, Vol. 1, pp. 1004-1010, 1996						
	74	Singh et al., "Immune therapy in inflammatory bowel disease and models of colitis", British Journal of Surgery, 88: 1558-1569, 2001						
	75	Tanaka, H. et al.' "Preparation and formulation of fused pyrimidine compounds as CRF receptor antagonists." Database accession no. 129:109098 HCA XP002121647						
EXAMINER				DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-AZ-PCT-US/JPW/GJG/ML		Serial No. 10/816,329	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelhana et al.			
					Filing Date March 31, 2004		Group	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	76	Van Niel, M.B. et al., "Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT _{1D} Receptor Ligands with Improved Pharmacokinetic Profiles" <i>J. Med. Chem.</i> (1999) 42(12): 2087-2104						
	77	West, R.A. et al. (1961) "2-alkyl(aryl)-and 2,7-dimethyl-4-substituted aminopyrrolo[2,3-d]pyrimidines." <i>J. Org. Chem.</i> , 26:3809-3812						
	78	Yan, Luo et al. (2003) Expert Opinion on Emerging Drugs, vol. 8, no. 2 pp. 537-576						
EXAMINER					DATE CONSIDERED			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								